Author

Gisela Müller

Observed name: Müller, Gisela

Institution: Swiss Group For Clinical Cancer Research

Observed institution: Swiss Group For Clinical Cancer Research

ORCID: 0009-0002-2993-8062

Observed ORCID: 0009-0002-2993-8062

OpenAlex ID: A5102519567

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial

2025 · Adalgisa Condoluci, Ilaria Romano, et al. · Blood · 10

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

2025 · Eugenio Fernandez, Rémi Vernet, et al. · Experimental Hematology and Oncology · 6

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

2024 · Michael Mark, Alfonso Rojas Mora, et al. · Bone Reports · 2

Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.

2023 · Tämer El Saadany, Ulf Petrausch, et al. · Journal of Clinical Oncology · 1

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

2025 · Fernandez, Eugenio, Vernet, Rémi, et al. · Zurich Open Repository and Archive (University of Zurich)

Works count: 6

Citation count: 19

H-index: 2

I10-index: 1